EDAPEDAP
Recorded

EDAP 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration35 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Patrick WoodHead of U.S. MedTech Research

You got me? Okay. Amazing. Thank you so much. Welcome, everybody. Patrick on the UBS MedTech team. Delighted to have Ryan of the FocalTherics team here to go through what should be an awesome intro to the company. I think, Ryan, you were planning on doing a little bit of a presentation first. I think there was some slides to go through, and then we can do some Q&A, if that works?

Patrick WoodHead of U.S. MedTech Research

Yeah. Amazing. Do we have the slides up?

Patrick WoodHead of U.S. MedTech Research

Just hit next. Thank you.

Ryan RhodesCEO

Thank you. So real quick, just by name, FocalTherics, focal to target, therapeutics is to treat and heal. We are the global leader in therapeutic ultrasound for both the treatment of cancer and benign disease, and we accomplish this by leaving the organ in place, treating only the disease. We spare the organ and thus preserve the functional outcomes of that organ and for the patient. If you look here, we have an ongoing commitment to growth of focal therapy, and as noted, not only growth, but momentum building here. EUR 16 million in revenue up to EUR 26 million through calendar year 2024. What is exciting is our growth is extending as we look at last year and, of course, our growth model for this year. 38% year-over-year growth is our target, revenue of approximately EUR 55 million.

Ryan RhodesCEO

We see growth, but we also see momentum building in our business. We are a platform technology that integrates all kinds of unique proprietary sub-technologies. So advanced imaging, we can bring imaging into our Focal One system from any source, whether it is an MRI that is marked up or a biopsy map, PSMA PET. We are current to all standards of imaging. Remote connectivity, we can tele-mentor doctors remotely, have the potential of doing teleservice or remote service, and we have even been able to treat patients remotely. We put out a press release a number of months ago. We treated a patient from Cleveland Clinic, Ohio, remotely, who is in Cleveland Clinic, Abu Dhabi in the Middle East, 7,000 miles away. We believe our technology sets up very well for that, and we are excited about a branded product we will be launching called Focal Connect. We are also an AI-driven treatment.

Ryan RhodesCEO

We have AI solutions for how we deliver our treatment. We have advanced robotics. We have a five-axis robotic positioning system, which is very robust, a key component of our platform. Then importantly to understand, we've been in sound-based therapy for well over 30 years. We were a formidable player in extracorporeal shockwave lithotripsy, sound-based therapy to break up kidney stones. We then developed all the unique technologies we offer today in HIFU. Because of our sound-based therapy and because it's part of our DNA, we're working on histotripsy. That was a key mention at our June investor day conference in New York. We filed some very important proprietary patents, and we're really exciting about that because that could give us an opportunity to not only treat with Focal One as a system with HIFU, but have in the future the potential for delivering histotripsy.

Ryan RhodesCEO

We're a unique platform that encompasses these technologies, but it also plays really well into the growth of new indications. Prostate cancer is the most common cancer diagnosed in men. This is a core focus for the company. As referenced, over 1.4 million men are diagnosed annually with prostate cancer. Within that subset, 300,000 plus are just diagnosed in the U.S. What's exciting or interesting to really understand is we have 3.5 million men walking around and living with their disease today. So it's a large market, a growing market, but a market that will double by calendar year 2040, and that's based on data from The Lancet consensus on prostate cancer. A large market, but a market that will double in the next 14 years. If you think of prostate cancer, it is a heterogeneous cancer. It's not one cancer, it's millions of cancers.

Ryan RhodesCEO

At time of diagnosis, you're risk stratified by the type of cancer you have. As shown, low risk, intermediate risk, and high risk. If you have low-risk prostate cancer, you might be commonly prescribed active surveillance or monitoring. If you have high-risk disease, you may be prescribed more aggressive therapy, surgery, and/or radiation. But what do you do for this large bolus of patients that fall into intermediate risk, which is about 50% of the newly diagnosed cases? Well, this is what we solve with Focal One robotic HIFU, shown in the blue bar or blue arrow. Really, there's been historically no good suitable treatment options, and there's a gap between these low-risk patients and high-risk patients. How do we categorically think of treating them? That's really one of the key theses of what problem we solve.

Ryan RhodesCEO

We're also a technology that's currently written into the NCCN, National Comprehensive Cancer Network, hospital guidelines as a salvage treatment for failed primary radiation therapy. In the clinical literature, radiation failures are cited anywhere from 15%-30%. Men who fail radiation don't have a lot of good options. Commonly, they'll be prescribed ADT or androgen deprivation therapy or hormone therapy. We're going to turn off your testosterone, technically chemically castrate you to lower your PSA. Though that may be effective, the side effects are drastic for a man to go through that, and they're refractive to treatment, meaning they have to cycle off of it. That's a very important thing to understand, and salvage surgery never typically leads to a very good outcome, especially when you think of functional outcomes, operating on a radiated pelvis.

Ryan RhodesCEO

We're, as mentioned in those guidelines, and that's another market opportunity for us. When you think of what the patient wants today, this 2-by-2, quality of life preservation against proven efficacy, we know active surveillance is not a treatment. It's a monitoring protocol, so it's going to score very high on quality of life preservation. We're not really doing anything. We're just monitoring you. But obviously, scores very low on proven efficacy. Surgery and radiation, however, score very high on efficacy. As treatments, they've been around for arguably close to 100 years, but quality of life preservation is always in question, how that patient will be after their surgery or multiple cycles of radiation. Really, what a patient wants is a highly efficacious procedure or treatment that preserves their quality of life, and that's what we accomplish with Focal One Robotic HIFU.

Ryan RhodesCEO

When we think of data today, in prostate cancer, it's all based around the trifecta outcomes. That is, cancer control being number 1, followed by preservation of urinary continence, and followed by preservation of sexual function. There's also a notion of patient burden. When you look at the literature today and you go through all the literature, how do these different treatments stack up? The good news is, with the data that's come out, the end of 2024, we have the HIFI study, which was 3,200 men across 46 centers, 80 urologists, and is a prospective multicenter study that was sponsored by the French government to look at efficacy-based outcomes to award reimbursement. You look at that study, landmark study, we'll never see a study likely of that size, at least in my lifetime, and that is a powerful data point.

Ryan RhodesCEO

We also know there's new studies coming out, FARP, Focal Ablation versus Radical Prostatectomy, which is a randomized control trial that will publish out soon, in the coming months. That's level 1 evidence, but it proves exactly what we saw with the HIFI study. When you add up all the different endpoints in the published data, what you see here is Focal One Robotic HIFU is not inferior to the gold standard treatments of surgery and radiation, but patients typically do far better on the quality of life outcomes, as shown by that 2-by-2 matrix I just showed earlier. Of course, the patient burden is low. We're talking about a short outpatient procedure that's typically delivered in a time of 40-60 minutes with optimal workflow and choreography, meaning patient in, patient out, arguably 90 minutes to one hour and 40 minutes.

Ryan RhodesCEO

We have the data now that proves the efficacy and reinforces the patient benefits in terms of preservation of quality of life. The market is moving now in this category shift to focal therapy. The traditional market, as referenced, is active surveillance, surgery, and radiation. We're now in this new emerging market in the middle, that pie chart in the middle. But at market maturity, focal therapy will represent a very large subset of this market, as shown here. I've had doctors argue with me that it'll be larger because we're advancing on multiple fronts. Imaging is advancing. We're also looking at combining therapies, HIFU with immunotherapy, such as a study that we're embarking on at Mount Sinai Hospital in New York. That's another important directive of where we're going with these new emerging non-invasive focal therapy technologies. We know the market is moving.

Ryan RhodesCEO

This is Medicare data in the category of focal therapy published out through calendar year 2025. As shown here, HIFU is the fastest-growing focal therapy treatment, and it has become the number one ablation technology for prostate cancer. We will likely see the continued momentum building as we get data here that will publish out next year on calendar year 2026. HIFU is growing. The reimbursement is strong to reinforce this growth. CPT code 55880 is a category 1 CPT code. We are really excited because last week, the final rule was published by Medicare, by CMS, and HIFU will go up double digits to an increase of 10.5%. That will be effective January 1st. Bear in mind, this number, 10,688, is a national average. It is adjusted based on wage labor index at point of care, where that hospital is located.

Ryan RhodesCEO

We happen to have an office in the San Francisco Bay Area. When we run an analysis like this, the payments are up around $14,000, even $15,000. Same would be in other major metropolitan markets. What does that all mean? It means that hospitals can invest in Focal One and build a durable, sustaining, high-growth focal therapy program. When you look at the physician reimbursement, what is important to understand is we award or is awarded HIFU 17.29 work RVUs, which is the highest of any physician-delivered focal therapy for prostate cancer. On the very bottom is surgery. I spent nearly 14 years of my career at Intuitive Surgical. It is only a $200 difference than surgery. Surgery arguably takes longer, has more staffing demands, more supply cost, more burden on the surgeon in delivering that surgery.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day